Current Status of Fecal Microbiota Transplantation for Inflammatory Bowel Disease Management.
作者信息
Allegretti Jessica R
机构信息
Director, Crohn's and Colitis Center Director, Fecal Microbiota Transplant Program Brigham and Women's Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts.
出版信息
Gastroenterol Hepatol (N Y). 2025 Jul;21(7):451-453.
Abstract
摘要
相似文献
1
Current Status of Fecal Microbiota Transplantation for Inflammatory Bowel Disease Management.粪便微生物群移植在炎症性肠病治疗中的现状
Gastroenterol Hepatol (N Y). 2025 Jul;21(7):451-453.
2
Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis.粪便微生物群移植治疗炎症性肠病：一项系统评价和荟萃分析。
J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13.
3
What's New and What's Next in Fecal Microbiota Transplantation?粪便微生物群移植的新进展与未来方向？
Biologics. 2025 Aug 21;19:481-496. doi: 10.2147/BTT.S486372. eCollection 2025.
4
The Role of Fecal Microbiota Transplantation in IBD.粪便微生物群移植在炎症性肠病中的作用
Microorganisms. 2024 Aug 23;12(9):1755. doi: 10.3390/microorganisms12091755.
5
Fecal microbiota transplantation for vancomycin-resistant Clostridium innocuum infection in inflammatory bowel disease: A pilot study evaluating safety and clinical and microbiota outcome.粪菌移植治疗炎症性肠病中耐万古霉素无害梭菌感染：一项评估安全性、临床及微生物群结局的初步研究
J Microbiol Immunol Infect. 2025 Oct;58(5):585-592. doi: 10.1016/j.jmii.2025.03.004. Epub 2025 Mar 4.
6
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.用于预防PUNCH CD3-OLS中炎症性肠病患者复发性艰难梭菌感染的活粪微生物群制剂-jslm（REBYOTA®）的安全性和有效性
Inflamm Bowel Dis. 2025 Jan 25. doi: 10.1093/ibd/izae291.
7
The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.粪便微生物群移植后炎症性肠病发作的风险：系统评价和荟萃分析。
Gut Microbes. 2017 Nov 2;8(6):574-588. doi: 10.1080/19490976.2017.1353848. Epub 2017 Sep 12.
8
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.基于微生物和针对微生物的疗法治疗炎症性肠病。
Dig Dis Sci. 2020 Mar;65(3):757-788. doi: 10.1007/s10620-020-06090-z.
9
Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Primer for Internists.炎症性肠病中的粪便微生物移植：内科医生入门。
Am J Med. 2018 Sep;131(9):1017-1024. doi: 10.1016/j.amjmed.2018.03.010. Epub 2018 Mar 29.
10
The current landscape of fecal microbiota transplantation in treating inflammatory bowel disease.粪便微生物群移植治疗炎症性肠病的现状
Transl Gastroenterol Hepatol. 2025 Jun 11;10:55. doi: 10.21037/tgh-24-138. eCollection 2025.
本文引用的文献
1
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.用于预防PUNCH CD3-OLS中炎症性肠病患者复发性艰难梭菌感染的活粪微生物群制剂-jslm（REBYOTA®）的安全性和有效性
Inflamm Bowel Dis. 2025 Jan 25. doi: 10.1093/ibd/izae291.
2
The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond.肠道微生态治疗学的进展：从胃肠道疾病治疗到其他领域
Gastroenterology. 2024 Oct;167(5):885-902. doi: 10.1053/j.gastro.2024.05.004. Epub 2024 May 14.
3
Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection.复发性艰难梭菌感染行粪便微生物移植后的炎症性肠病结局。
Inflamm Bowel Dis. 2021 Aug 19;27(9):1371-1378. doi: 10.1093/ibd/izaa283.
4
Fecal transplantation for ulcerative colitis: current evidence and future applications.粪便移植治疗溃疡性结肠炎：现有证据和未来应用。
Expert Opin Biol Ther. 2020 Apr;20(4):343-351. doi: 10.1080/14712598.2020.1733964. Epub 2020 Feb 26.
5
Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.粪便微生物群移植维持克罗恩病缓解：一项初步随机对照研究。
Microbiome. 2020 Feb 3;8(1):12. doi: 10.1186/s40168-020-0792-5.
6
Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease.粪便微生物群移植在炎症性肠病治疗中的作用洞察。
Therap Adv Gastroenterol. 2019 Mar 14;12:1756284819836893. doi: 10.1177/1756284819836893. eCollection 2019.
Zotero 插件